1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. BENITEC BIOPHARMA INC
Benitec Biopharma Inc
XNAS: BNTC
Download real time
8.29-0.34(-3.94%)
New 52W Low today
162.5K
XNAS Volume

XNAS 14 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Benitec Biopharma Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Benitec Biopharma Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEUTRAL

    Quarterly Revenue Benitec Biopharma Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • POSITIVE

    Quarterly Net Profit Benitec Biopharma Inc Jun-2026 Quarterly Net Profit is $-13 Million which is growth of 20.7% YoY.

Benitec Biopharma Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
0
Cost Of Rev.
----------0.1-
Gross Profit
---------0.1-
⌄
14.413.613.49.817.210.28.65.85.64.16.95.94.6
Operating Profit
-14.4-13.6-13.4-9.8-17.2-10.2-8.6-5.8-5.6-4.1-6.9-5.9-4.6
⌄
1.61.61.4110.80.80.60.9-0-0-0
Profit Before Tax
-12.8-11.9-11.8-9-16.2-9.4-7.4-5.1-4.7-4.3-6.8-6-4.7
Tax
-------------
⌄
-12.8-11.9-11.8-9-16.2-9.4-7.4-5.1-5.3-4.3-6.8-6-4.7
Diluted NI Avail to Com Stockholders Ann.
-12.8-11.9-11.8-9-16.2-9.4-7.4-5.1-5.3-4.3-6.8-6-4.7
Basic EPS
-0.3-0.2-0.3-0.2-0.4-0.2-0.3-0.51.4-1.6-2.6-2.8-2.7
Diluted EPS After ExtraOrdinary
-0.3-0.2-0.3-0.2-0.4-0.2-0.3-0.5-0.5-1.6-2.7-2.7-2.7
Number Of Shares End
49.449.44641.541.238.622.110.610.12.62.62.21.6
Net Income Continuing Discontinued Operations
-12.8-11.9-11.8-9-16.2-9.4-7.4-5.1-4.7-4.3-6.8-6-4.7
Normalized Income
-6.6-4.3-4.5-3.8-2.7-6.8-6.4-4.6-4.3-4.1-6.7-5.9-4.5
Interest Income
-1.6----0.8------
Interest
---------000
Net Interest Income
1.61.61.4110.80.80.60.9-0-0-0
EBIT
-14.4-13.5-13.2-10-17.2-10.2-8.2-5.7-5.6-4.3-6.8-6-4.7
EBITDA
-14.3-13.4-13.1-9.9-17.1-10.1-8.1-5.6-5.6-4.2-6.7-5.9-4.6
Reconciled Cost Of Rev.
----------0.1-
Reconciled Depr.
0.10.10.10.10.10.10.10.10.10.10.10.10.1
Profit From Continuing Operations
-12.8-11.9-11.8-9-16.2-9.4-7.4-5.1-4.7-4.3-6.8-6-4.7
Normalized EBITDA
-14.3-13.5-13.4-9.6-17.2-10.1-8.2-5.8-5.5-4.1-6.9-5.8-4.6
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Benitec Biopharma Inc competitor comparison and performance snapshot within industry

Benitec Biopharma Inc annual results: revenue, profit, P&L, and margins as of Jun 2026 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEUTRAL

    Annual Revenue Benitec Biopharma Inc Annual Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Annual Net Profit Benitec Biopharma Inc Annual Net Profit is $-46 Million which is growth of -20.1% YoY.

Benitec Biopharma Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMJun '26Jun '25Jun '24Jun '23Jun '22Jun '21Jun '20Jun '19Jun '18Jun '17Jun '16
⌄
-
-
 0.10.10.10.111.30.50.50.4
Cost Of Rev. Ann.
-
-
 ---00.1-0.20.40.30.20.1
Gross Profit Ann.
-
-
 ---0.10.1-0.10.310.90.10.20.2
Operating Exp. Ann.
38.7%
30.6%
51.251.241.822.519.217.913.58.48.48.74.416.2
Operating Profit Ann.
-
-
-51.2-51.2-41.8-22.5-19.1-17.9-13.6-8.32.5-8.6-4.2-16
⌄
-
-
5.65.63.30.9-0-0-00.10.1---
Other Exp. Ann.
-
-
 0.10.6-0.2-0.5-0.3-0.3-0.10.2-0.2-2.5
PBT Ann.
-
-
-45.5-45.6-37.9-21.8-19.6-18.2-13.9-8.32.9-8.6-4.4-18.5
Tax Ann.
-
-
 --------
⌄
-
-
-45.5-45.6-37.9-22.4-19.6-18.2-13.9-8.32.9-8.6-4.4-18.5
Diluted NI Avail to Com Stockholders Ann.
-
-
-45.5-45.6-37.9-22.4-19.6-18.2-13.9-8.32.9-8.6-4.4-18.5
EPS Ann.
-
-
 -1-1.1-5.5-14.1-37.9-54.9-137.758-218.5-124.5-646.3
Diluted EPS Ann.
-
-
 -1-1.1-5.5-14.1-37.9-54.9-137.758-218.5-124.5-646.3
Number Of Shares End
213.7%
150.6%
 49.441.210.11.60.50.50.10.900.10
Total Exp. Ann.
38.7%
30.2%
 51.241.822.519.217.913.78.48.894.616.3
Net Income Continuing Discontinued Operations Ann.
-
-
-45.5-45.6-37.9-21.8-19.6-18.2-13.9-8.32.9-8.6-4.4-18.5
Normalized Income Ann.
-
-
-19.1-19.1-20.5-20.9-19.1-17.3-13.3-83.3-8.7-3.9-14.6
Interest Income Ann.
-
-
 ------00.10.1---
Interest Ann.
-
-
 ---00------
EBITDA Ann.
-
-
-50.6-50.6-40.8-22.3-19.2-17.8-13.5-83-8.9-4.1-18
Reconciled Cost Of Rev. Ann.
-
-
 ---00.1-0.20.40.30.20.1
Reconciled Depr. Ann.
7.7%
4.6%
0.50.50.40.30.40.40.40.40.20.10.2-
Profit From Continuing Operations Ann.
-
-
-45.5-45.6-37.9-21.8-19.6-18.2-13.9-8.3----
Normalized EBITDA Ann.
-
-
-50.8-50.8-41.3-22.2-18.7-17.5-12.9-7.82.5-8.4-3.8-13.4
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Operating Exp. Ann.
1Y CHG
22.5%
2Y CAGR
50.8%
3Y CAGR
38.7%
5Y CAGR
30.6%
7Y CAGR
29.5%
10Y CAGR
12.2%
Operating Expenses Annual Cr growth is lower than historical averages.

Benitec Biopharma Inc balance sheet as of Jun 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Benitec Biopharma Inc Jun-2026 Total Shareholders Fund is $177 Million which is growth of 81.9% YoY.

  • POSITIVE

    Total Assets Benitec Biopharma Inc Jun-2026 Total Assets is $183 Million which is growth of 83.4% YoY.

Benitec Biopharma Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsJun '26Jun '25Jun '24Jun '23Jun '22Jun '21Jun '20Jun '19Jun '18Jun '17Jun '16
⌄
243.6%
53.5%
182.699.652.24.5621.411.619.215.717.414.9
⌄
9.2%
32%
5.62.354.33.11.41.42.61.90.90.8
⌄
860.1%
54.7%
17797.347.30.22.92010.216.613.816.514.1
Total Capitalization Ann.
860.1%
54.7%
17797.347.30.22.92010.216.613.816.514.1
Tangible Assets Ann.
860.1%
54.7%
17797.347.30.22.92010.216.613.816.514.1
Working Capital Ann.
-
55.8%
176.396.746.8-0.32.319.29.716.113.516.213.7
Invested Capital Ann.
860.1%
54.7%
17797.347.30.22.92010.216.613.816.514.1
Tangible Book Value Ann.
860.1%
54.7%
17797.347.30.22.92010.216.613.816.514.1
Borrowings Ann.
10.1%
32%
0.80.90.30.60.80.20.4----
Net Debt Ann.
-
-
-----------
Share Issued Ann.
172.5%
133.1%
34.426.310.11.70.50.51.10.90.90.70.5
Number Of Shares End
213.7%
150.6%
49.441.210.11.60.50.50.10.900.10
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
83.3%
2Y CAGR
87%
3Y CAGR
243.6%
5Y CAGR
53.5%
7Y CAGR
38%
10Y CAGR
28.5%
Total Assets Annual growth is stable compared to historical averages.
Total Current Liabilities Ann.
1Y CHG
194.4%
2Y CAGR
4%
3Y CAGR
9.8%
5Y CAGR
30.5%
7Y CAGR
10.7%
10Y CAGR
20.8%
Total Current Liabilities Annual Cr growth is higher than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
81.9%
2Y CAGR
93.4%
3Y CAGR
860.1%
5Y CAGR
54.7%
7Y CAGR
40.2%
10Y CAGR
28.8%
Total ShareHolders Funds Annual growth is stable compared to historical averages.

Benitec Biopharma Inc ROE, ROCE, book value, and debt-to-equity ratio as of Jun 2026 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share Benitec Biopharma Inc Book Value Per Share is $5 which is growth of 43.3% YoY.

  • NEUTRAL

    ROE Benitec Biopharma Inc ROE is 0% which is growth of 0% YoY.

Benitec Biopharma Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsJun '26Jun '25Jun '24Jun '23Jun '22Jun '21Jun '20Jun '19Jun '18Jun '17Jun '16
RoA Ann. %
-
-
--49.96%-78.94%-374.86%-133.14%-84.22%-53.74%16.44%-51.68%-27.10%-107.49%
ROE Ann. %
-
-
--52.46%-94.29%-1,268.61%-159.08%-91.79%-61.73%18.90%-56.45%-28.58%-114.29%
ROIC %
-
-
--16.4-18-152.6-83.7-25.5-27.6--16.3-11.4-26.1
OPM Ann. %
-
-
----25,441.33%-24,457.53%-23,044.07%-8,537.11%22.43%-1,877.73%-924.41%-4,606.20%
Inventory Turnover Ratio Ann.
-
-
-----------
Asset Turnover Ann. %
-
-
---0000.7000
Working Capital Turnover Ann.
-
-
-0.3000.7000
Quick Ratio Ann.
-
-
-54.310.40.61.614.58.76.9819.518.6
Current Ratio Ann.
-
-
-54.710.50.91.915.19.57.18.219.718.7
Interest Coverage Ratio Ann.
-
-
----591.8-568------
LT Debt To Equity Ann.
-
-
-0-1.40.2-0----
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Benitec Biopharma Inc cash flow: net, operating, investing, and financing flows as of Jun 2026 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Cash From Operating Activity Benitec Biopharma Inc Cash From Operating Activity is $-17 Million which is growth of 30.0% YoY.

  • POSITIVE

    Net Cash Flow Benitec Biopharma Inc Net Cash Flow is $82 Million which is growth of 75.7% YoY.

Benitec Biopharma Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsJun '26Jun '25Jun '24Jun '23Jun '22Jun '21Jun '20Jun '19Jun '18Jun '17Jun '16
⌄
-
-
-16.5-23.6-19.4-18-15.9-12.8-7.5----
⌄
-
-
-0.1-0-0.2-0-0.2-0.1-0.4-0.1-0.2-0.3
⌄
83.6%
34.5%
9970.5681622.51.86.36.113.1
Cash Plus Cash Eqv. End Of Year Ann.
316.1%
55.5%
180.197.950.92.54.119.89.815.711.813.413.6
Net Increase In Cash Plus Cash Eqv.s Ann.
-
54%
82.446.948.5-2-15.99.5-5.93.7-1.1-0.5-2.3
Cash Plus Cash Eqv. Begin Of Year Ann.
188%
58.5%
97.950.92.54.119.89.815.711.312.81416.3
Income Tax Paid Supplemental Data Ann.
-
-
-----------
Interest Paid Supplemental Data Ann.
-
-
-----------
Capex Ann.
-
-
-0.1-0-0.2-0-0.2-0.1-0.4-0.1-0.1-0.3
Issuance Of Capital Stock Ann.
80.1%
32.3%
104.530.573.917.925.82.36.56.214.5
Issuance Of Debt Ann.
-
-
-----------
Repayment Of Debt Ann.
-
-
-----------
Repurchase Of Capital Stock Ann.
-
-
-----------
Free Cash Flow Ann.
-
-
-16.6-23.6-19.6-18-15.9-13.1-7.63.8-7.7-6.4-15
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
40.4%
2Y CAGR
20.7%
3Y CAGR
83.6%
5Y CAGR
34.5%
10Y CAGR
22.4%
Cash from Financing Annual Activity growth is stable compared to historical averages.
×